中国神经再生研究(英文版) ›› 2021, Vol. 16 ›› Issue (11): 2213-2214.doi: 10.4103/1673-5374.310675

• 观点:退行性病与再生 • 上一篇    下一篇

苯丙胺类兴奋剂致帕金森病机制的生物物理学研究进展

  

  • 出版日期:2021-11-15 发布日期:2021-04-13

A biophysical perspective on the unexplored mechanisms driving Parkinson’s disease by amphetamine-like stimulants

Carla Ferreira, Joana Couceiro, Sandra Tenreiro, Alexandre Quintas   

  1. Molecular Pathology and Forensic Biochemistry Laboratory, Centro de Investigação Interdisciplinar Egas Moniz, P-2825-084 Caparica, Portugal (Ferreira C, Couceiro J, Quintas A)
    Laboratório de Ciências Forenses e Psicológicas Egas Moniz, Campus Universitário–Quinta da Granja, Monte de Caparica, P-2825-084 Caparica, Portugal (Ferreira C, Couceiro J, Quintas A)
    Faculty of Medicine of Porto University, Al. Prof. Hernâni Monteiro, P-4200–319 Porto, Portugal (Ferreira C)
    iNOVA4Health, CEDOC,  NOVA Medical School, NMS, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal (Tenreiro S) 
  • Online:2021-11-15 Published:2021-04-13
  • Contact: Alexandre Quintas, PhD, alexandre.quintas@gmail.com.
  • Supported by:
    CF, JC, AQ were supported by Egas Moniz Cooperativa de Ensino Superior. ST was supported by Fundação para a Ciência e Tecnologia project 02/SAICT/2017/029656 and iNOVA4Health-UIDB/04462/2020, a program financially supported by Fundação para a Ciência e Tecnologia/Ministério da Educação e Ciência, Portugal, through national funds and co-funded by FEDER under the PT2020 Partnership Agreement.  

摘要:

Neural Regen Res使用苯丙胺类兴奋剂易增加患帕金森病的风险

 

流行病学研究发现苯丙胺类兴奋剂使用者一生中患帕金森病的风险增加。来自葡萄牙格兰塔·格拉哈大学的Alexandre Quintas团队发表文章证实了这一点,并提出了从分子水平上研究苯丙胺类兴奋剂对α-突触核蛋白影响的实验框架。该实验方法显示了绘制α-突触核蛋白多肽链聚集的热力学和动力学图的重要性。Alexandre Quintas团队也研究了苯丙胺类兴奋剂对蛋白质构象和聚集动力学的影响。由于蛋白质质量控制的正常功能取决于能量代谢,而能量代谢随着年龄的增长而减少,因此α-突触核蛋白修饰可能成为涉及这些化合物的特发性帕金森病病例的潜在诱因。他们认为对苯丙胺类兴奋剂的暴露可能通过氧化应激直接或间接地促进非程序化α-突触核蛋白翻译后修饰,改变其热力学和动力学格局,稳定易于形成有毒聚集体和最终淀粉样蛋白的中间体。

 

文章在《中国神经再生研究(英文版)》杂志202111 月  11 期发表。

https://orcid.org/0000-0002-5188-0453 (Alexandre Quintas)

Abstract: Epidemiological studies have reported an increased risk of Parkinson’s disease (PD) development in amphetamine-type stimulant users during their lifetime (Garwood et al., 2006; Rumpf et al., 2017). Protein inclusions mainly composed of misfolded and aggregated α-synuclein are the pathological hallmark of PD and other disorders known as synucleinopathies. Molecular studies present evidence that amphetamine upregulates α-synuclein synthesis in substantia nigra. The increment of α-synuclein levels promotes its aggregation and amyloid fibril formation, increasing  reactive oxygen species (ROS), and consequently dopamine oxidation (Wang and Witt, 2014), known to be toxic for dopaminergic neurons involved in motor function and limbic-motor integration. Over the years, these damaged cells lose their functionality and may die precociously, depleting the reserve of neural cells necessary for the normal neurological function which contributes to the onset of PD, when a critical number of cells are lost (Garwood et al., 2006). Therefore, the use of amphetamine-type stimulants may be a trigger event in the development of PD and parkinsonism, in conjugation to other risk factors that a given individual may hold. Despite the evidence, a previous study suggests that there is not enough data to corroborate the loss of dopamine neurons due to human amphetamine-type stimulant exposure, and consequently its implication in the PD development (Kish et al., 2017). Thus, elucidating the mechanisms underlying amphetamine-type stimulant influence on PD may contribute to better knowledge about the risk factors for the onset of this disease by these substances and adopt social policies to prevent future cases. The present perspective highlights the uncharted spots of the molecular mechanisms of α-synuclein aggregation pathways and how additional studies are necessary to understand the role of amphetamine-like stimulants as triggers of PD by changing α-synuclein thermodynamic and kinetic landscape.